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Background: We aimed to evaluate the performance of serum cystatin C-based
equations in calculating the glomerular ﬁltration rate (GFR) in patients with varying
stages of chronic kidney disease (CKD).
Methods: Serum cystatin C and creatinine levels were measured in 615 CKD
patients. The CKD stage was determined by the creatinine-based estimated GFR
(eGFR) equation using the four-variable abbreviated Modiﬁcation of Diet in Renal
Disease equation suggested by the Kidney Disease Outcome Quality Initiative with
the addition of a coefﬁcient applicable to Korean populations (K-aMDRD). In each
CKD stage, the ratio of serum cystatin C to creatinine was calculated and six
different cystatin C-based equations were used to estimate GFR. Cystatin C-based
eGFR and aMDRD eGFR values were compared using the paired t test, Pearson
correlation test, and the Bland–Altman plot.
Results: The mean age of patients was 53.21714.45 years; of the 615 patients, 346
were male. The serum cystatin C-to-creatinine ratio was inversely correlated with
the CKD stage. Compared with the K-aMDRD values, the results of the Hoek, Filler,
and Le Bricon’s cystatin C-based eGFR equations were lower in CKD Stages 1–3 and
higher in Stages 4 and 5. However, the results of the Orebro-cystatin (Gentian)
equation [GFR¼100/ScytC (mL/minute/1.73 m2) – 14] were similar to those of the
K-aMDRD equation in CKD Stages 4 and 5 (15.4479.45 vs. 15.1779.05 mL/minute/
1.73 m2, respectively; P¼0.722; bias¼0.2778.87).
Conclusion: The eGFRs obtained from the six cystatin C-based equations differed
widely. Therefore, further studies are required to determine the most accurate
equation to estimate GFR in Koreans with CKD.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
gy, Pusan National Uni-
602–739, Korea.Introduction
Estimation of the glomerular ﬁltration rate (GFR) is the
most important step in the diagnosis of chronic kidney disease
(CKD), and signiﬁcant research has been directed toward
developing the most accurate, convenient, and reproducible
equation. Traditionally, the Modiﬁcation of Diet in Renalshed by Elsevier. This is an open access article under the CC BY-NC-ND
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Disease Epidemiology Collaboration (CKD-EPI) [3] equations
have been considered the most acceptable creatinine-based
equations for estimating GFR. The Kidney Disease Outcome
Quality Initiative (K/DOQI) recommends using an abbreviated
form of the MDRD equation (aMDRD) for clinical purposes [4].
A recent publication by Lee et al [5] adapted the aMDRD
equation for a Korean population by adding a coefﬁcient
(K-aMDRD), which improved the estimated GFR (eGFR) per-
formance and more closely approximated inulin clearance.
However, there are a number of disadvantages in using serum
creatinine itself as a ﬁltration marker [6,7]. Therefore, identify-
ing a new endogenous ﬁltration marker is necessary for the
accurate and convenient estimation of GFR.
Serum cystatin C is a cationic nonglycosylated low-
molecular-weight cysteine proteinase inhibitor produced at a
constant rate by all nucleated cells and freely ﬁltered at the
glomerulus [8]. Approximately 99% of ﬁltered cystatin C is
reabsorbed in the proximal tubule, where it undergoes near-
complete catabolization [9,10]. Because of these features,
serum cystatin C was proposed as a superior marker of GFR,
and its superiority over serum creatinine in the early detection
of acute kidney injury is already well established [11,12].
However, its role as a ﬁltration marker is still conﬂicting
[13–15], and there is no validated cystatin C-based eGFR equation
in predicting the glomerular rate in CKD patients [16–20].
Thus, in this study, we aimed to determine the performance
of cystatin C in estimating GFR and the accuracy of six different
cystatin C-based eGFR equations and compared the results with
that of the K-aMDRD equation according to the CKD stage.Methods
Patients
Serum creatinine and cystatin C levels were measured in 615
CKD patients who visited the Pusan National University Hospital
between January 2011 and December 2011. The recruited patients
were aged Z18 years. Patients with thyroid dysfunction, inﬂam-
mation, severe liver disease, or a history of steroid therapy were
excluded [21–23]. Patients with extremely high eGFR calculated
using the MDRD equation (eGFR4130mL/minute/1.73 m2) [5]
and patients with end-stage renal disease on maintenance dialysis
were also excluded. The local Ethics Committee approved this
study to analyze anonymous, routinely collected clinical data and
waived the requirement of informed consent.
Laboratory methods
Serum creatinine and serum cystatin C levels were mea-
sured in the same serum sample. Serum creatinine values
were measured by the alkaline picrate Jaffe kinetic method,
and cystatin C values were determined by turbidimetry-based
immunoassays using reagents from Healthcare Innovation
(HBI Co, Anyang, Korea). The ratio of serum cystatin C to
creatinine (mg/L to mg/dL) was calculated without adjustment
of the unit for ease of application.
GFR measurement and estimation
Measured GFR
The measured GFR (mGFR) was obtained by Tc-99m-
diethylenetriamine pentaacetate (Tc-99m-DTPA) renalscintigraphy. After a bolus injection of 10-mCi Tc-99m-DTPA,
GFR was obtained using the Gates method [24] during a renal
scan with VERTEX (EPIC) gamma camera equipped with
ADAC's DUAL DETECTOR (ADAC, Milpitas, CA, USA).eGFR by serum creatinine
Serum creatinine-based eGFR was calculated by the CKD-
EPI [3] and K-aMDRD equations [GFR¼107.904  Scr1.009 
age0.02 (0.667 if woman)] [5]. The CKD stage was classiﬁed
according to the recommendation of the Kidney Disease
Improving Global Outcomes and National Kidney Founda-
tion-K/DOQI guideline using the K-aMDRD equation [25].eGFR by serum cystatin C
Serum cystatin C-based eGFR was calculated using six
different equations published previously. Larsson A et al [16]: GFR¼99.43  ScytC1.5837
(mL/minute/1.73 m2) Hoek FJ et al [17]: GFR¼80.35/ScytC4.32 (mL/minute/
1.73 m2) Le Bricon T et al [18]: GFR¼78/ScytCþ4 (mL/minute/
1.73 m2) Filler G and Lepage N [19]: GFR¼91.62  ScytC1.123
(mL/minute/1.73 m2) Orebro-cystatin (DAKO) [19]: GFR¼119/ScytC – 33 (mL/
minute/1.73 m2) Orebro-cystatin (Gentian) [19]: GFR¼100/ScytC – 14
(mL/minute/1.73 m2)
Statistical analysis
Data were analyzed using SPSS for Windows, version 17.0
(SPSS Inc., Chicago, IL, USA). The Student t test was used for
analysis of continuous variables and results are presented as
mean7standard deviation (SD). The Chi-square test was used
for analysis of categorical variables. Differences in eGFR in each
of the CKD stage were compared using a paired t test. The
mean difference (bias) between the paired observation is given
with SD (precision) and P values. The Bland–Altman plot was
used to test the agreement between eGFRs from the K-aMDRD
formula and the cystatin C-based equations, as well as
between the K-aMDRD and mGFR [26]. Values of Po0.05
were considered statistically signiﬁcant.Results
Baseline characteristics
A total of 615 patients were enrolled in this study. The mean
age of the recruited patients was 53.21714.45 years with
56.3% of patients being male. Patients with diabetes mellitus
comprised 23.9% of the study population and hypertensive
patients comprised 35.1%. The mean serum creatinine level
was 2.5273.14 mg/dL and the mean serum cystatin C level
was 1.7971.18 mg/L. The mean and upper 99th percentile
serum cystatin C, respectively, according to the stages of CKD
were as follows: CKD 1, 0.8770.20 mg/L and 1.45 mg/L; CKD 2,
1.2070.43 mg/L and 2.20 mg/L; CKD 3, 1.9470.49 mg/L and
3.08 mg/L; CKD 4, 3.1370.61 mg/L and 4.29 mg/L; CKD 5
Table 2. Validation of the abbreviated MDRD equation with the
Korean coefﬁcient in CKD 4 and 5 (N¼21)
Mean (SD)
(mL/minute/1.73 m2)
Bias Precision P R
mGFR 18.04 (8.57) – – – –
MDRD [5] 20.29 (6.28) 2.25 7.86 0.204 0.475
CKD, chronic kidney disease; MDRD, Modiﬁcation of Diet in Renal
Disease; mGFR, measured glomerular ﬁlatration rate; SD, standard
deviation.
Figure 1. The Bland–Altman plot for differences between GFR mea-
sured by DTPA renal scan and the abbreviated MDRD equation with
the Korean coefﬁcient. The mean difference is indicated by the center
line. Limits of agreement are indicated by the upper (meanþ2SD) and
lower (mean – 2SD) lines. DTPA, diethylenetriamine pentaacetate; GFR,
glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet in Renal Disease;
SD, standard deviation.
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according to the CKD stage are summarized in Table 1.
Validation of the aMDRD equation with Korean coefﬁcient
Of the 615 patients, 21 patients (CKD 4¼16, CKD 5¼5)
underwent a nuclear medicine renal scan using DTPA. The
mean mGFR was 19.1878.72 mL/minute/1.73 m2 in CKD 4 and
13.1976.74 mL/minute/1.73 m2 in CKD 5. The correlation
coefﬁcient between mGFR and eGFR was 0.5 (P¼0.03). The
Bland–Altman plot analysis of the degree of correspondence
between the eGFR calculated by the K-aMDRD formula and the
mGFR using DTPA scan revealed that the majority of results fell
within the 95% conﬁdence interval (Table 2, Fig. 1).
Cystatin C-to-creatinine ratio according to the CKD stage
Fig. 2A shows the cystatin C-to-creatinine ratios; the mean
ratio was 0.9570.33 (mg/L to mg/dL). In CKD Stages 1–3, the
serum cystatin C level nearly coincided with the serum
creatinine level. However, in CKD Stages 4 and 5, the serum
cystatin C level did not increase as expected, and the cystatin
C-to-creatinine ratio decreased to 0.7570.16 (mg/L to mg/dL)
in CKD Stage 4, and to 0.4970.16 (mg/L to mg/dL) in CKD
Stage 5 (Fig. 2B).
Comparison of cystatin C-based eGFRs
Compared with the results of the K-aMDRD equation, the
cystatin C-based equations estimated a lower GFR in CKD
Stages 1–3, but presented differing results in Stages 4 and 5.
Compared with the results of CKD-EPI, cystatin C-based eGFRs
were higher in all the CKD stages (Table 3).
The eGFRs using serum cystatin C with the six different
equations were slightly different when the GFR got lower. In
particular, when compared with the K-aMDRD equation, the
Hoek, Filler, and Le Bricon’s equations yielded higher eGFRs,
whereas the Orebro-cystatin (DAKO) equation yielded lower
eGFRs (Fig. 3).
We measured the concordance between the GFRs estimated
by each cystatin C-based equation and the K-aMDRD equation.
Filler’s equation yielded the most similar eGFRs in CKD Stages
1–3 (74.77728.26 mL/minute/1.73 m2 vs. 75.17728.26 mL/
minute/1.73 m2; P¼0.622, bias¼0.39716.09), whereas the
Orebro-cystatin (Gentian) equation yielded the most similarTable 1. Baseline patient characteristics
Characteristic Total (N¼615) CKD 1 (N¼204) CKD 2 (N¼
Age (y) 53.21714.45 48.24714.78 56.3271
Male 346 (56.3) 119 (58.3) 74 (52
DM 147 (23.9) 26 (12.7) 29 (20
HT 215 (35.1) 31 (15.2) 43 (30
SBP (mmHg) 124.98715.81 122.31712.19 122.4071
DBP (mmHg) 78.93711.40 77.6879.86 78.0671
MAP (mmHg) 92.72716.80 91.19714.77 90.8571
Hb (g/dL) 12.4372.39 13.9471.65 13.3671
Alb (g/dL) 4.1970.59 4.4070.54 4.4070
sCr (mg/dL) 2.5273.14 0.8270.19 1.1970
sCystC (mg/L) 1.7971.18 0.8770.20 1.2070
CystC/Cr 0.9570.33 1.0970.29 1.0270
Data are presented as N (%) or mean7standard deviation.
Alb, albumin; CKD, chronic kidney disease; CystC/Cr, cystatin C-to-creati
hemoglobin; HT, hypertension; MAP, mean arterial pressure; SBP, systolic beGFRs in Stages 4 and 5 (15.4479.45 mL/minute/1.73 m2 vs.
15.1779.05 mL/minute/1.73 m2; P¼0.722, bias¼0.2778.87;
Table 3). Accordingly, the Bland–Altman plot showed the highest
concordance with Filler’s equation in Stages 1–3, and the Orebro-
cystatin (Gentian) equation in Stages 4 and 5 (Fig. 4).140) CKD 3 (N¼137) CKD 4 (N¼71) CKD 5 (N¼63)
2.71 56.24713.33 58.24713.14 49.76715.58
.9) 74 (54.0) 45 (63.4) 29 (46.0)
.7) 50 (36.5) 23 (32.4) 19 (30.1)
.7) 63 (46.0) 38 (56.5) 40 (63.5)
3.76 128.51718.63 129.72719.11 134.92723.81
0.48 80.66713.21 80.07712.15 84.69716.15
7.10 95.19718.03 94.87718.53 101.43718.21
.85 12.0471.96 10.4771.44 9.1071.52
.42 4.0970.55 3.9670.56 3.5470.61
.29 2.0670.57 4.3771.30 9.8274.77
.43 1.9470.49 3.1370.61 4.2570.74
.39 0.9770.21 0.7570.16 0.4970.16
nine ratio; DBP, diastolic blood pressure; DM, diabetes mellitus; Hb,
lood pressure; sCr, serum creatinine; sCystC, serum cystatin C.
Figure 2. Cystatin C-to-creatinine ratio according to the CKD stage. (A) Relationship between serum creatinine and serum cystatin C. (B) The
cystatin C-to-creatinine ratio according to the CKD stage. The ratio decreases with advancing stages. CKD, chronic kidney disease.
Table 3. Estimated glomerular ﬁltration rate
Variable Total CKD 1 CKD 2 CKD 3 CKD 4 CKD 5
Creatinine-based eGFR (mL/minute/1.73 m2)
MDRD [5] 63.81736.05 106.90710.75 76.9778.69 45.1878.10 22.2974.67 7.1175.28
CKD-EPI [3] 54.54735.79 92.46723.56 62.94714.31 33.0578.39 13.6874.14 5.8372.23
Cystatin-based eGFR (mL/minute/1.73 m2)
Larsson A et al [16] 54.16736.96 100.51720.44 76.19724.66 38.80714.30 17.0474.83 10.6973.12
Hoek FJ et al [17] 57.86731.45 89.89717.59 69.63719.06 39.34710.24 23.13711.84 15.1673.49
Le Bricon T et al [18] 64.24730.42 95.26716.89 73.85718.51 46.3979.94 30.64711.49 22.9173.39
Filler G and Lepage N [19] 64.01734.27 101.76717.88 78.69721.15 46.37712.18 27.4279.78 18.7073.78
Orebro-cystatin (DAKO) [19] 52.13741.47 97.47720.58 70.55724.96 31.67715.16 5.7376.84 4.1475.18
Orebro-cystatin (Gentian) [19] 59.69736.35 98.47718.55 78.85721.86 40.35712.74 18.5575.75 10.2574.35
Data are presented as mean7standard deviation.
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular ﬁltration rate; MDRD,
Modiﬁcation of Diet in Renal Disease.
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We evaluated the performance of serum cystatin C and the
cystatin C-based eGFR equations and compared the results with
that of the K-aMDRD equation according to the CKD stage. Inulin
clearance and other methods using injected radioactive substances
such as 52Cr-ethylenediaminetetraacetic acid, Tc-99m-DTPA are
considered the true reference standards for determining GFR.
Unfortunately, these tests are expensive and laborious, and there-
fore are not suited to clinical practice. In our cross-sectional
retrospective study, we did not measure inulin clearance and
performed DTPA renal scans in only 21 patients. Therefore, we
were unable to compare the cystatin C-based estimates of GFRs
with the true reference GFR. However, the recently proposed K-
aMDRD equation is based on inulin clearance [5], and the MDRD
equation has been previously validated in patients with CKD
[27,28]. In addition, although the number of patients was limited
in our study, the Bland–Altman plot showed agreement between
the K-aMDRD eGFR and the GFR measured by DTPA renal scans in
21 patients with CKD Stages 4 and 5. These ﬁndings suggest the
validity of having used the K-aMDRD equation as a reference
rather than as the true reference GFR.
We found that the cystatin C-based eGFR equations yielded
values that differed greatly depending on the CKD stage.Overall, in Stages 1–3, the eGFRs were lower than those
calculated by the K-aMDRD equation, whereas the results
differed by equation in Stages 4 and 5.
As previously reported, serum cystatin C concentration may
underestimate renal dysfunction in advanced CKD because
cystatin C did not increase along with the CKD stage, and the
cystatin C-to-creatinine ratio decreased with advancing CKD
stage [29]. It has been hypothesized that the discrepancy
between serum creatinine and cystatin C may be due to extra-
renal clearance of cystatin C [20]. In our study, the cystatin C-to-
creatinine ratio was comparable with previously published
values (Fig. 2), and the estimated rates from Hoek, Filler, and
Le Bricon’s equations were greater than those from the K-aMDRD
equation in CKD Stages 4 and 5 (Table 4), as the previously cited
group suggested [20]. By contrast, we found that the Orebro-
cystatin (Gentian) equation generated eGFR values comparable
with those of the K-aMDRD equation in all CKD stages.
In the Orebro-cystatin (Gentian) equation, unlike the other
cystatin C-based eGFR equations, both the production rate and
extrarenal clearance of cystatin C are taken into account [30]. This
could prevent an overestimation of eGFR in patients with CKD
Stage 4 or 5.
The Orebro-cystatin (DAKO) equation also considered the
extrarenal elimination of cystatin C, and this equation used the
same template as the Orebro-cystatin (Gentian) equation [19].
Figure 3. Comparison of cystatin C-based equations and the abbreviated MDRD equation with the Korean coefﬁcient. (A) Correlations of eGFR
between cystatin C-based equations and the abbreviated MDRD equation with the Korean coefﬁcient. The thin line indicates an identical line; the bold line
shows the ﬁt of the data. (B) The Bland - Altman plots between each cystatin C-based eGFR and the abbreviated MDRD equation. Difference is plotted as the
percentage of differences with the average; the regression line of the difference is also presented. The mean difference is indicated by the center line; limits
of agreement are indicated by the upper (meanþ2SD) and lower (mean – 2SD) lines. The Filler equation showed the least mean difference from baseline,
while the Orebro Gentian equation regression analysis revealed no trend toward overestimation as GFR decreased. CKD-EPI, chronic kidney disease
epidemiology collaboration; eGFR, estimated glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet in Renal Disease; SD, standard deviation.
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with the eGFR calculated using the K-aMDRD equation,
because the reagents used in the determination of serum
cystatin C levels were different. Tidman et al [30] reported
that serum cystatin C determined by the Gentian method was
approximately 40% higher than the DAKO method in the low
GFR range. This may explain the differing results of the DAKO
and Gentian equations. In our study, cystatin C was measuredby turbidimetric methods using HBI reagents produced in
Korea, which differ from the Gentian methods. Nonetheless,
the Gentian equation generated eGFRs comparable with those
generated by the K-aMDRD equation in patients with CKD
Stages 4 and 5. Based on previously published literature,
creatinine-based MDRD equations are known to underestimate
the GFR in patients with a GFR460 mL/minute/1.73 m2 [31]. By
contrast, we found the eGFR from the K-aMDRD equation to be
Figure 4. Magniﬁcation of the Bland–Altman plot that shows best concordance with the abbreviated MDRD equation: the Filler equation in
early-stage CKD and the Orebro Gentian equation in advanced CKD. CKD, chronic kidney disease; MDRD, Modiﬁcation of Diet in Renal Disease.
Table 4. Cystatin C-based eGFRs, bias, and precision compared with related to the abbreviated MDRD equation with the Korean coefﬁcient
according to CKD stage
Variable Mean (SD)
(mL/minute/1.73 m2)
Bias Precision P R
CKD Stages 1–3
MDRD [5] 75.17 (28.26) – – – –
Larsson A et al [16] 67.85 (32.14) 3.27 18.51 0.001 0.818
Hoek FJ et al [17] 66.72 (26.11) 11.28 15.65 o0.001 0.827
Le Bricon T et al [18] 72.82 (25.21) 5.11 15.44 o0.001 0.827
Filler G and Lepage N [19] 74.77 (28.26) 0.39 16.09 0.622 0.828
Orebro-cystatin (DAKO) [19] 65.58 (33.53) 9.58 18.78 o0.001 0.830
Orebro-cystatin (Gentian) [19] 70.80 (29.61) 5.58 16.41 o0.001 0.835
CKD Stages 4 and 5
MDRD [5] 15.12 (9.03) – – – –
Larsson A et al [16] 14.04 (5.18) 0.99 6.87 0.097 0.652
Hoek FJ et al [17] 19.38 (9.77) 4.27 9.91 o0.001 0.447
Le Bricon T et al [18] 27.01 (9.48) 11.89 9.74 o0.001 0.447
Filler G and Lepage N [19] 22.56 (5.85) 7.52 6.76 o0.001 0.662
Orebro-cystatin (DAKO) [19] 1.05 (7.85) 13.97 7.00 o0.001 0.664
Orebro-cystatin (Gentian) [19] 14.62 (6.59) 0.42 6.77 0.480 0.664
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet in Renal Disease; SD, standard deviation.
Kidney Res Clin Pract 33 (2014) 45–5150higher than those from the cystatin C-based equations. This may
be due to improved accuracy of the modiﬁed equation [5], or
possibly due to the superior performance of cystatin C as an early
marker of GFR decline [32,33].
The eGFRs produced by the six cystatin C-based equations
differed widely. We found that Filler’s equation yielded results
most similar to those of the K-aMDRD equation in CKD Stages
1–3, whereas the Orebro-cystatin (Gentian) equation per-
formed similarly in CKD Stages 4 and 5. However, given the
lack of a true reference GFR in our study, we are unable to
conclude that these equations are the most accurate.
In summary, the eGFRs calculated by the six cystatin
C-based equations differed from each other and from those
calculated by the K-aMDRD equation. Therefore, further study
is needed to determine the most suitable equation to estimate
GFR in Koreans with CKD.Conﬂicts of interest
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